# APUS (Apimeds Pharmaceuticals US, Inc.) - SEC EDGAR Financial Statements

> Apimeds Pharmaceuticals US, Inc. reported $153.5M in total assets and a net loss of $22.74M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/APUS
- Markdown: https://convexityos.com/fundamentals/APUS.md
- SEC CIK: 0001894525
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:10 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001894525&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$23.47M | Operating profit |
| Net Income | FY 2025 | -$22.74M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$5.07 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$8.98M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $18K | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $1.63M | -- | $99K |
| Total Operating Expenses | $11.91M | $1.28M | -- |
| **Operating Income** | -$11.91M | -$1.28M | -$747K |
| **EBITDA** | -$11.91M | -- | -- |
| Interest Income | $108K | $2.8K | $7.8K |
| Interest Expense | $283K | $118K | $38K |
| **Net Income** | -$6.00M | -$1.39M | -$778K |
| Basic EPS | -$5.50 | -$1.80 | -$1.70 |
| **Diluted EPS** | -$5.50 | -$1.80 | -$1.70 |
| Basic Shares Outstanding | 1.1M | 790.4K | 459.8K |
| Diluted Shares Outstanding | 1.1M | 790.4K | -- |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $2.90M | $283K | -- | -- | -- | -- | -- | -- |
| Cost of Revenue | $54K | -- | -- | -- | -- | -- | -- | -- |
| **Gross Profit** | $2.84M | -- | -- | -- | -- | -- | -- | -- |
| Research & Development | -- | $960K | $901K | -- | $620K | $652K | -- | -- |
| Total Operating Expenses | -- | $6.28M | $12.19M | $7.04M | $1.84M | $2.66M | $364K | -- |
| **Operating Income** | $2.03M | -$6.28M | -$12.19M | -$7.04M | -$1.84M | -$2.66M | -$364K | -$276K |
| **EBITDA** | -- | -$6.27M | -$12.17M | -- | -- | -$2.66M | -- | -- |
| Interest Income | -$22K | $22K | $7 | $36K | $56K | $15K | $3 | $30 |
| Interest Expense | $1.09M | $3.22M | $859K | $216K | $6.3K | $23K | $38K | $36K |
| **Net Income** | $33.65M | -$20.17M | -$35.06M | -$1.16M | -$1.78M | -$2.66M | -$402K | -$312K |
| Basic EPS | $19.13 | -$11.77 | -$22.60 | -- | -$1.42 | -$2.57 | -$0.50 | -- |
| **Diluted EPS** | $7.68 | -$11.77 | -$22.60 | -- | -$1.42 | -$2.57 | -$0.50 | -- |
| Basic Shares Outstanding | 1.8M | 1.7M | 1.6M | -- | 1.3M | 1.0M | 790.4K | -- |
| Diluted Shares Outstanding | 4.5M | 1.7M | 1.6M | -- | 1.3M | 1.0M | 790.4K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $145K | $3.5K | $410K |
| Short-Term Investments | $2.00M | -- | -- |
| **Cash & Short-Term Investments** | $2.14M | $3.5K | $410K |
| Other Current Assets | $48K | -- | -- |
| **Total Current Assets** | $13.98M | $13K | $422K |
| Property, Plant & Equipment, Net | $52K | -- | -- |
| **Total Non-Current Assets** | $150.2M | $0 | $0 |
| **Total Assets** | $164.2M | $13K | $422K |
| Accounts Payable | $424K | -- | -- |
| **Total Current Liabilities** | $10.71M | $1.02M | $123K |
| **Total Non-Current Liabilities** | $129K | $347K | $267K |
| **Total Liabilities** | $10.84M | $1.37M | $390K |
| **Total Debt (incl. Leases)** | $169K | -- | -- |
| Common Stock | $1.3K | $79K | $79K |
| Retained Earnings | -$10.39M | -$4.39M | -$3.00M |
| **Total Stockholders' Equity** | $153.3M | -$1.36M | $32K |
| Total Equity | $153.3M | -$1.36M | $32K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $18K | $278K | $980K | $145K | $6.99M | $8.74M | $250K | $3.5K |
| Short-Term Investments | -- | -- | $1.50M | $2.00M | -- | -- | -- | -- |
| **Cash & Short-Term Investments** | $18K | $278K | $2.48M | $2.14M | $6.99M | $8.74M | $250K | $3.5K |
| Accounts Receivable, Net | $2.48M | -- | -- | -- | -- | -- | -- | -- |
| Other Current Assets | $78K | $49K | $48K | $48K | -- | -- | -- | -- |
| **Total Current Assets** | $10.85M | $10.68M | $13.15M | $13.98M | $9.09M | $10.35M | $260K | $13K |
| Property, Plant & Equipment, Net | -- | $52K | $57K | $52K | $34K | $13K | -- | -- |
| **Total Non-Current Assets** | $142.7M | $116.9M | $128.1M | $150.2M | $164K | $197K | $0 | $0 |
| **Total Assets** | $153.5M | $127.6M | $141.2M | $164.2M | $9.25M | $10.55M | $260K | $13K |
| Accounts Payable | $1.35M | $2.09M | -- | $424K | -- | -- | -- | -- |
| Deferred Revenue (Current) | $278K | -- | -- | -- | -- | -- | -- | -- |
| **Total Current Liabilities** | $13.01M | $21.07M | $14.58M | $10.71M | $1.09M | $809K | $1.77M | $1.02M |
| **Total Non-Current Liabilities** | $0 | $102K | $119K | $129K | $0 | $0 | $250K | $347K |
| **Total Liabilities** | $13.01M | $21.18M | $14.70M | $10.84M | $1.09M | $809K | $2.02M | $1.37M |
| **Total Debt (incl. Leases)** | -- | $161K | $171K | $169K | -- | -- | -- | -- |
| Common Stock | $1.8K | $1.5K | $126K | $1.3K | $126K | $126K | $79K | $79K |
| Retained Earnings | -$31.98M | -$65.63M | -$45.45M | -$10.39M | -$9.24M | -$7.46M | -$4.79M | -$4.39M |
| **Total Stockholders' Equity** | $140.5M | $106.4M | $126.5M | $153.3M | $8.16M | $9.74M | -$1.76M | -$1.36M |
| Total Equity | $140.5M | $106.4M | $126.5M | $153.3M | $8.16M | $9.74M | -$1.76M | -$1.36M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$6.00M | -$1.39M | -$778K |
| Depreciation & Amortization | $5.7K | -- | -- |
| Stock-Based Compensation | $1.57M | $70K | $70K |
| **Operating Cash Flow** | -$8.93M | -$734K | -$628K |
| Capital Expenditure | -$57K | -- | -- |
| **Free Cash Flow** | -$8.98M | -- | -- |
| Acquisitions, Net | $15K | -- | -- |
| **Investing Cash Flow** | -$10.06M | -- | -- |
| Common Stock Issued | $11.63M | -- | $1.05M |
| **Financing Cash Flow** | $20.62M | $326K | $1.03M |
| **Net Change in Cash** | $1.63M | -$407K | $404K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | $33.65M | -$20.17M | -$35.06M | -$1.16M | -$1.78M | -$2.66M | -$402K | -$312K |
| Depreciation & Amortization | -- | $4.7K | $20K | -- | -- | $232 | -- | -- |
| Stock-Based Compensation | -- | $105K | -- | $109K | $1.74M | $192K | $0 | -- |
| **Operating Cash Flow** | -$219K | -$5.67M | -$2.07M | -$3.82M | -$1.73M | -$3.36M | -$20K | -$100K |
| Capital Expenditure | $0 | $0 | -$9.4K | -- | -- | -- | -- | -- |
| **Free Cash Flow** | -$219K | -$5.67M | -$2.08M | -- | -- | -- | -- | -- |
| **Investing Cash Flow** | -$53K | $1.50M | $491K | -- | -- | -- | -- | -- |
| **Financing Cash Flow** | $11K | $3.47M | $920K | $8.49M | $0 | $11.86M | $267K | -- |
| **Net Change in Cash** | -$260K | -$701K | -$657K | -$5.35M | -$1.75M | $8.48M | $247K | -$23K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Equity (ROE) | -3.9% | -- | -2440.3% |
| Return on Assets (ROA) | -3.7% | -10645.6% | -184.3% |
| Current Ratio | 1.31x | 0.01x | 3.42x |
| Quick Ratio | 0.20x | 0.00x | 3.33x |
| Debt to Equity | 0.00x | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -16.2% | -54.6% | -32.1% | -3.9% | -63.2% | -38.1% | -- | -- |
| Return on Assets (ROA) | -14.8% | -45.6% | -28.8% | -3.7% | -55.8% | -35.2% | -575.6% | -10645.6% |
| Current Ratio | 0.83x | 0.51x | 0.90x | 1.31x | 8.34x | 12.79x | 0.15x | 0.01x |
| Quick Ratio | 0.19x | 0.01x | 0.17x | 0.20x | 6.41x | 10.80x | 0.14x | 0.00x |
| Debt to Equity | -- | 0.00x | 0.00x | 0.00x | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
